Nitazoxanide


Full Generic Medicine Info
Dosage/Direction for Use

Oral
Cryptosporidiosis, Giardiasis
Adult: 500 mg 12 hourly for 3 days.
Child: 1-3 years 100 mg 12 hourly; 4-11 years 200 mg 12 hourly for 3 days. >12 years Same as adult dose. All doses to be taken for 3 days.
Administration
Should be taken with food.
Contraindications
Hypersensitivity.
Special Precautions
Patient with HIV and immunodeficiency. Pregnancy and lactation.
Adverse Reactions
Gastrointestinal disorders: Nausea, vomiting, abdominal pain, diarrhoea, gastroesophageal reflux disease. Nervous system disorders: Headache, dizziness. Renal and urinary disorders: Chromaturia. Respiratory, thoracic and mediastinal disorders: Dyspnoea. Skin and subcutaneous tissue disorders: Skin rash, urticaria.
Food Interaction
Increased AUC with food.
Action
Nitazoxanide is an antiprotozoal agent which impairs the anaerobic metabolism of susceptible organisms via the interference of the pyruvate:ferredoxin oxidoreductase (PFOR) enzyme-dependent electron transfer reaction. In vitro, it inhibits the growth of sporozoites and oocysts of Cryptosporidium parvum and the trophozoites of Giardia lamblia.
Absorption: Absorbed from the gastrointestinal tract. Time to peak plasma concentration: 1-4 hours (as tizoxanide and tizoxanide glucuronide).
Distribution: Plasma protein binding: >99% (tizoxanide).
Metabolism: Rapidly hydrolysed to tizoxanide (active desacetyl metabolite) which partially undergoes further conjugation, primarily by glucuronidation.
Excretion: Via faeces (approx 67%) and urine (approx 33%). Elimination half-life: 1-1.6 hours (tizoxanide).
Storage
Oral: Store at 25°C.
CIMS Class
Antiamoebics
ATC Classification
P01AX11 - nitazoxanide ; Belongs to the class of other agents used in the treatment amoebiasis and other protozoal diseases.
Disclaimer: This information is independently developed by CIMS based on nitazoxanide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in